Pembrolizumab
Highest phase reached
Approved
Drug type
Antibody
First approval year
2014
- First approval year
- 2014
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Antibody
- Drug name
- Pembrolizumab
- keytruda
- Keytruda
- pembrolizumab component of mk 1308a
- pembrolizumab component of mk 7684a
- Pembrolizumab component of mk 7684a
- Pembrolizumab component of mk-1308a
- 200 mg pembrolizumab
- 200 mg Pembrolizumab
- Drug: Pembrolizumab
- immunoglobulin g4 anti human protein pdcd1 programmed cell death 1 human mus musculus monoclonal heavy chain disulfide with human mus musculus monoclonal light chain dimer
- IMMUNOGLOBULIN G4, ANTI-(HUMAN PROTEIN PDCD1 (PROGRAMMED CELL DEATH 1)) (HUMAN-MUS MUSCULUS MONOCLONAL HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL LIGHT CHAIN, DIMER
- Immunotherapy (pembrolizumab)
- Immunotherapy (Pembrolizumab)
- keylynk 010 component pembrolizumab
- KEYLYNK-010 COMPONENT PEMBROLIZUMAB
- Keytruda
- KEYTRUDA ®( Pembrolizumab)
- keytruda qlex component pembrolizumab
- KEYTRUDA QLEX COMPONENT PEMBROLIZUMAB
- Keytruda®
- KEYTRUDA®
- Keytruda® (pembrolizumab)
- KEYTRUDA® (pembrolizumab)
- KEYTRUDA®, Pembrolizumab
- Keytruda®(china)
- lambrolizumab
- Lambrolizumab
- MK - 3475
- mk 1308a component pembrolizumab
- mk 3475
- mk 7684a component pembrolizumab
And 72 more, listed on the interactive page.
- ATC classification codes
- L01FF02
Sources for recorded values
- CAS registry numbers
- 1374853-91-4
- ChEMBL ID
- CHEMBL3137343
- RxNorm IDs (RxCUI)
- 1547545
- FDA ingredient codes (UNII)
- DPT0O3T46P
- Applicant
- MERCK SHARP DOHME
- Approval date
- 4 Sept 2014
- Application number
- BLA125514
- Status
- Authorised
- Status date
- 17 Jul 2015
- Authorisation date
- 17 Jul 2015
- Approved indications
- Melanoma Keytruda as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma. Keytruda as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, IIC, or with Stage III melanoma and lymph node involvement who have undergone complete resection. Non small cell lung carcinoma (NSCLC) Keytruda, in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, is indicated for the treatment of resectable non small cell lung carcinoma at high risk of recurrence in adults Keytruda as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum based chemotherapy (for selection criteria, see section 5.1). Keytruda as monotherapy is indicated for the first line treatment of metastatic non small cell lung carcinoma in adults whose tumours express PD L1 with a ≥ 50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations. Keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non squamous non small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations. Keytruda, in combination with carboplatin and either paclitaxel or nab paclitaxel, is indicated for the first line treatment of metastatic squamous non small cell lung carcinoma in adults. Keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic non small cell lung carcinoma in adults whose tumours express PD L1 with a ≥ 1% TPS and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received targeted therapy before receiving KEYTRUDA. Malignant pleural mesothelioma (MPM) Keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first‑line treatment of adults with unresectable non-epithelioid malignant pleural mesothelioma. Classical Hodgkin lymphoma (cHL) Keytruda as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option. Urothelial carcinoma Keytruda, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, is indicated for the treatment of adults with resectable muscle invasive bladder cancer (MIBC) who are ineligible for cisplatin‑containing chemotherapy. Keytruda, in combination with enfortumab vedotin, is indicated for the first-line treatment of unresectable or metastatic urothelial carcinoma in adults. Keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum containing chemotherapy.Keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin containing chemotherapy and whose tumours express PD L1 with a combined positive score (CPS) ≥ 10. Head and neck squamous cell carcinoma (HNSCC) Keytruda as monotherapy is indicated for the treatment of resectable locally advanced head and neck squamous cell carcinoma as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adults whose tumours express PD-L1 with a CPS ≥ 1. Keytruda, as monotherapy or in combination with platinum and 5 fluorouracil (5 FU) chemotherapy, is indicated for the first line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD L1 with a CPS ≥ 1. Keytruda as monotherapy is indicated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express PD L1 with a ? 50% TPS and progressing on or after platinum containing chemotherapy. Renal cell carcinoma (RCC) Keytruda, in combination with axitinib, is indicated for the first line treatment of advanced renal cell carcinoma in adults. Keytruda, in combination with lenvatinib, is indicated for the first line treatment of advanced renal cell carcinoma in adults. Keytruda as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions (for selection criteria, please see section 5.1). Microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) cancers Colorectal cancer (CRC)Keytruda as monotherapy is indicated for theadults with MSI-H or dMMR colorectal cancer in the following settings: first line treatment of metastatic microsatellite instability high (MSI H) or mismatch repair deficient (dMMR) colorectal cancer in adults; treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine based combination therapy. Non-colorectal cancersKeytruda as monotherapy is indicated for the treatment of the following MSI H or dMMR tumours in adults with: advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation; unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. Oesophageal carcinoma Keytruda, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus in adults whose tumours express PD L1 with a CPS ≥ 10. Triple negative breast cancer (TNBC) Keytruda, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence. Keytruda, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express PD L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease. Endometrial carcinoma (EC) Keytruda, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults who are candidates for systemic therapy. Keytruda, in combination with lenvatinib, is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation. Cervical cancer Keytruda, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is indicated for the treatment of FIGO 2014 Stage III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy. Keytruda, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD L1 with a CPS ≥ 1. Gastric or gastro-oesophageal junction (GEJ) adenocarcinoma Keytruda, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1. Keytruda, in combination with fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD L1 with a CPS ≥ 1 (see section 5.1). Biliary tract carcinoma (BTC) Keytruda, in combination with gemcitabine and cisplatin, is indicated for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults. Ovarian Cancer Keytruda, in combination with paclitaxel, with or without bevacizumab, is indicated for the treatment of platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma in adults whose tumours express PD‑L1 with a CPS ≥ 1 and who have received one or two prior systemic treatment regimens.
- Product number
- EMEA/H/C/003820
- Authorisation holder
- Merck Sharp & Dohme B.V.
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Transitional Cell
- Endometrial Neoplasms
- Hodgkin Disease
- Melanoma
- Squamous Cell Carcinoma of Head and Neck
- Urologic Neoplasms
European medicines record
- Patents
- 0
- Designations
- 8
- Earliest recorded loss of exclusivity
- 25 Jan 2031
- First in class
- Yes
- Fast track
- No
- Breakthrough designation
- Yes
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- Yes
- Availability
- Prescription only
- Pharmacology name
- pembrolizumab
- Type
- Antibody
- Drug name stem
- -mab; -mab
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
- Action
- Binding
- Action type
- Binding
- Target
- programmed cell death 1 (CD279)
- Gene symbol
- PDCD1
- Protein identifier
- Q15116
- Median affinity
- 10
- Affinity units
- pKd
- Primary target
- Yes
- Mechanism
- Programmed cell death protein 1 inhibitor
- Action type
- Inhibitor
- Target
- Programmed cell death protein 1
- Protein identifier
- Q15116
Open Targets mechanisms
- Mechanism
- Programmed cell death protein 1 inhibitor
- Action type
- Inhibitor
- Target
- Programmed cell death protein 1
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000094
- Subject identifier
- D015456
- Condition
- Leukemia, Lymphocytic, Chronic, B-Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000095
- Subject identifier
- D015451
- Condition
- Lymphoma, Follicular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000096
- Subject identifier
- D008224
- Condition
- Sarcoma, Ewing
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000174
- Subject identifier
- D012512
- Condition
- Squamous Cell Carcinoma of Head and Neck
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000181
- Subject identifier
- D000077195
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Hodgkin Disease
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000196
- Subject identifier
- D011471
- Condition
- Myelodysplastic Syndromes
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000198
- Subject identifier
- D009190
- Condition
- Lymphoma, T-Cell, Peripheral
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000211
- Subject identifier
- D016411
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Adenocarcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000228
- Subject identifier
- D000230
- Condition
- Carcinoma, Adenoid Cystic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000231
- Subject identifier
- D003528
- Condition
- Astrocytoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000272
- Subject identifier
- D001254
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000294
- Subject identifier
- D001749
- Condition
- Breast Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000305
- Subject identifier
- D001943
- Condition
- Carcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000313
- Subject identifier
- D002277
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000349
- Subject identifier
- D002292
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000365
- Subject identifier
- D015179
- Condition
- Melanoma
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000389
- Subject identifier
- D008545
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Carcinoma, Intraductal, Noninfiltrating
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0000432
- Subject identifier
- D002285
- Condition
- Adenocarcinoma, Follicular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000501
- Subject identifier
- D018263
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000503
- Subject identifier
- D013274
And 174 more, listed on the interactive page.
- Condition identifier
- EFO_0000095
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000096
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000181
- Condition identifier
- EFO_0000182
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000183
- Condition identifier
- EFO_0000196
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000198
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000199
- Condition identifier
- EFO_0000211
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000222
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000228
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000231
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000272
- Condition identifier
- EFO_0000294
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000305
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000313
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000365
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000389
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000403
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000432
- Condition identifier
- EFO_0000503
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000519
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000558
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000571
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 2
And 360 more, listed on the interactive page.
- Event
- adrenal insufficiency
- Reports
- 698
- Reporting signal score
- 1,408.16
- Event
- autoimmune colitis
- Reports
- 195
- Reporting signal score
- 660.103
- Event
- colitis
- Reports
- 1,461
- Reporting signal score
- 2,493.36
- Event
- fulminant type 1 diabetes mellitus
- Reports
- 237
- Reporting signal score
- 794.691
- Event
- hepatitis
- Reports
- 608
- Reporting signal score
- 619.024
- Event
- hyperthyroidism
- Reports
- 547
- Reporting signal score
- 871.829
- Event
- hypophysitis
- Reports
- 561
- Reporting signal score
- 1,772.82
- Event
- hypothyroidism
- Reports
- 1,081
- Reporting signal score
- 1,839.92
- Event
- immune-mediated adverse reaction
- Reports
- 305
- Reporting signal score
- 1,052.84
- Event
- immune-mediated enterocolitis
- Reports
- 459
- Reporting signal score
- 1,603.11
- Event
- immune-mediated hepatitis
- Reports
- 267
- Reporting signal score
- 882.152
- Event
- immune-mediated hypothyroidism
- Reports
- 48
- Reporting signal score
- 210.5
- Event
- immune-mediated myocarditis
- Reports
- 60
- Reporting signal score
- 242.625
- Event
- immune-mediated pneumonitis
- Reports
- 65
- Reporting signal score
- 264.736
- Event
- injection site pain
- Reports
- 4
- Reporting signal score
- 549.567
- Event
- interstitial lung disease
- Reports
- 277
- Reporting signal score
- 233.16
- Event
- malignant neoplasm progression
- Reports
- 2,830
- Reporting signal score
- 5,076.76
- Event
- myasthenia gravis
- Reports
- 291
- Reporting signal score
- 606.783
- Event
- myocarditis
- Reports
- 449
- Reporting signal score
- 767.5
- Event
- nephritis
- Reports
- 105
- Reporting signal score
- 250.77
- Event
- pemphigoid
- Reports
- 428
- Reporting signal score
- 768.134
- Event
- pneumonitis
- Reports
- 1,318
- Reporting signal score
- 2,439.17
- Event
- therapy partial responder
- Reports
- 116
- Reporting signal score
- 212.892
- Event
- thyroiditis
- Reports
- 330
- Reporting signal score
- 803.585
- Event
- tubulointerstitial nephritis
- Reports
- 479
- Reporting signal score
- 590.28
And 3 more, listed on the interactive page.
- NCT01042379
- NCT01676753
- NCT02129556
- NCT02447003
- NCT02555657
- NCT02646748
- NCT02657889
- NCT02730130
- NCT02734290
- NCT02752685
- NCT02768701
- NCT02819518
- NCT02990845
- NCT02999477
- NCT03025035
- NCT03025880
- NCT03032107
- NCT03051659
- NCT03051672
- NCT03121352
- NCT03139851
- NCT03145961
- NCT03197389
- NCT03222856
- NCT03225547
And 1,363 more, listed on the interactive page.
- Dose
- 200 mg or 400 mg
- Route
- Intravenous
- How often
- Every 3 weeks or every 6 weeks
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Heavy chain
- Type
- Protein
- Sequence
- QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
- Component
- Light chain
- Type
- Protein
- Sequence
- EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- 0006-3026
- 0006-3083
- 0006-5083
Related records
Trials (2,527)
- 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
- 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
- 1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck
- 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN
- 4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC
- 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
- 64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression
- 89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer
- 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
- A Beta-only IL-2 ImmunoTherapY Study
- A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
- A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma
- A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
- A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)
- A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
- A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
- A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
- A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
- A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Approved for (24)
- Cancer
- Classic Hodgkin lymphoma
- Clear cell renal carcinoma
- Collecting duct carcinoma
- Cutaneous melanoma
- Endometrial cancer
- Endometrial carcinoma
- Endometrium neoplasm
- Head and neck squamous cell carcinoma
- Hodgkins lymphoma
- Laryngeal squamous cell carcinoma
- Melanoma
- Metastatic melanoma
- Neoplasm
- Non-small cell lung carcinoma
- Oropharynx squamous cell carcinoma
- Papillary renal cell carcinoma
- Renal carcinoma
- Renal cell adenocarcinoma
- Renal cell carcinoma
In development for (180)
- Acral lentiginous melanoma Phase 2
- Acute myeloid leukemia Phase 2
- Adenocarcinoma Phase 2
- Adenoid cystic carcinoma Phase 2
- Adrenal cortex carcinoma Phase 2
- Adult glioblastoma Phase 2
- Adult lymphoma Phase 2
- Alveolar soft part sarcoma Phase 2
- Anal carcinoma Phase 2
- Anaplastic astrocytoma Phase 1
- Angiosarcoma Phase 2
- Anus cancer Phase 2
- Astrocytoma (excluding glioblastoma) Phase 1
- B-cell acute lymphoblastic leukemia Phase 1
- B-cell chronic lymphocytic leukemia Phase 2
- Bile duct carcinoma Phase 1
- Biliary tract cancer Phase 3
- Biliary tract neoplasm Phase 3
- Bone sarcoma Phase 2
- Brain cancer Phase 3
Other linked conditions (1)
- Oral cavity squamous cell carcinoma
Targets (1)
- PDCD1 Programmed cell death protein 1 inhibitor